Ck Life Sciences

CK Life Sciences, a Hong Kong-headquartered Pharmaceutical Preparation Manufacturing company, reported its most recent Scope 1 and 2 carbon emissions for 2024. The company's Scope 1 emissions, from direct operations, were approximately 31,245,000 kg CO2e, and its Scope 2 emissions, from purchased electricity, were approximately 16,250,000 kg CO2e. This resulted in combined Scope 1 and 2 emissions of approximately 47,495,000 kg CO2e for 2024.

For 2023, CK Life Sciences reported Scope 1 emissions of approximately 32,037,000 kg CO2e and Scope 2 emissions of approximately 16,923,000 kg CO2e, totalling approximately 48,960,000 kg CO2e for Scope 1 and 2. In 2022, the company's Scope 1 emissions were approximately 30,517,000 kg CO2e and Scope 2 emissions were approximately 16,363,000 kg CO2e.

CK Life Sciences has set a long-term Net Zero target for all scopes, aiming for 2050, with a start year of 2019. The company's emissions data is sourced directly from CK Life Sciences Int'l., (Holdings) Inc. and is not cascaded from a parent or related organization.